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Abstract
Background: The canonical Wnt signaling is concurrently important for osteoblast differentiation and myeloma cell
proliferation. Its activation in myeloma cells and its inhibition in osteoblasts and their progenitors have been
identified in the previous studies. Osteoblast progenitors and myeloma cells from a myeloma patient share the
same bone marrow (BM) microenvironment, but respond differently to DKK-1 secreted by myeloma cells. The
mechanisms remain unclear.
Methods: Primary multiple myeloma (MM) cells were isolated from BM mononuclear cells of 12 MM patients. Human
bone marrow stromal cells (SCs) were obtained from BM adherent cells of these MM patients and 10 healthy donors.
The mRNA expression levels of DKK-1 binding receptor LRP5/6 and Kremen1/2 (Krm1/2) were analyzed by Real-time
PCR in human myeloma cell line (HMCL) RPMI-8226, NCI-H929, U266, LP-1, CZ-1, KM-3, Sko-007, primary myeloma
cells and SCs from 12 MM patients and SCs from 10 healthy donors. The binding capability of DKK-1 binding
receptors to DKK-1 on primary myeloma cells and SCs was detected by flow cytometry assay.
Results: The mRNA expression levels of DKK-1 binding receptor LRP5/6 and Krm1/2 in SCs from patients with MM
were significantly higher than those in myeloma cells and in SCs from healthy donors. The binding capability to
DKK-1of DKK-1 binding receptors on SCs from MM patients was obviously higher than those on myeloma cells and
SCs from healthy donors by flow cytometry assay. Similar to the effects of coculture with rhDKK1, coculture of SCs
from healthy donors with myeloma cells in the presence or absence of a Transwell insert did up-regulate SCs’
mRNA levels of LRP5/6 and Krm1/2, and down-regulate their mRNA levels of b-catenin.
Conclusion: Compared with myeloma cells, the SCs from MM patients overexpress DKK-1 binding receptors LRP5/6
and Krm1/2 in response to DKK-1 secreted by myeloma cells, which results in intracellular Wnt signaling inhibition.
Our study provides a novel insight into mechanisms of myeloma associated osteolytic lesions.
Background
Multiple myeloma (MM) is one of hematological malig-
nancies characterized by bone marrow (BM) infiltration
of monoclonal plasma cells and progression of osteolytic
bone lesions [1]. It has been clearly identified that
myeloma cells and osteolytic bone lesions are interde-
pendent in that myeloma cells promote the development
of the associated bone disease, and the microenviron-
ment created by the resorbing bone in turn supports the
growth and survival of myeloma cells, thus resulting in
a vicious cycle of increased tumor burden and aggravat-
ing osteolytic bone disease [2,3]. MM associated bone
loss is thought to be mediated by an uncoupled or
imbalanced bone remodelling process with increased
osteoclastic bone resorption and decreased osteoblastic
bone formation [4]. It is only in the past few years that
the suppression of osteoblastogenesis was found to con-
tribute to the systemic bone loss and osteolytic bone
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osteoclast activation [5]. The deficit of bone formation
is attributable to osteoblastic dysfunction resulting from
the proliferation of myeloma cells in the BM. However,
the mechanisms by which myeloma cells affect the
formation and function of osteoblasts are still under
investigation.
Increasing evidences suggest that Wnt/b-catenin
signaling activation has been linked to many human
malignancies, including hematologic malignancies. It has
been reported that MM cells have hallmarks of activated
Wnt signaling [6]. In comparison with normal B-cell
populations, MM cells express high levels of b-catenin,
including the stabilized unphosphorylated form which
functions in activating T-cell factor/lymphoid enhancer
factor (TCF/LEF)-mediated transcription of target genes,
thus stimulating the proliferation of MM cells [7].
Interestingly, the canonical Wnt pathway is essential
to osteoblast differentiation and bone formation in addi-
tion to its role in tumor growth. Canonical Wnt signal-
ing encourages osteoblast differentiation, proliferation
and mineralization, while blocks apoptosis of osteoblasts
[8]. The Wnt signaling antagonist dickkopf 1(DKK-1)
has been shown to prevent Wnt-mediated terminal dif-
ferentiation of mesenchymal stem cells (MSC) and
osteoblast progenitors into osteoblasts. Furthermore, it
has been reported that MM cells produce DKK-1, and a
correlation between its expression by microarray analy-
sis and the presence of MM associated bone lesions has
been identified [9,10].
The role of Wnt signaling in MM seems to be a com-
plexity allowing for its activation in myeloma cells and
its inhibition in osteoblast progenitors. It is now well
recognized that the interaction between tumors and
their associated stroma can dramatically influence not
only the tumor but also the behavior of the stroma. In
t h es a m et u m o r - s t r o m am i l i e u ,D K K - 1p r o d u c e db y
MM cells could inhibit the Wnt signaling in osteoblasts
and their progenitors, but failed to block the Wnt signal
transduction in MM cells. Since the myeloma cells and
the stromal cells (SCs) share the same BM microenvir-
onment containing the ligand DKK-1, the determinant
contributing to the different Wnt signal transduction
may lie in the DKK-1 binding receptor expression.
The secreted protein DKK-1 interacts with the single-
pass transmembrane proteins Kremen1/2 (Krm1/2) and
the human low-density lipoprotein receptor-related
protein 5/6 (LRP5/6) to form a ternary complex and to
promote endocytosis and removal of LRP5/6 from the
cell surface membrane, thereby inhibiting Wnt signaling
[11,12]. In the present study, we first confirmed the
DKK-1 protein expression in both MM cell lines and
primary myeloma cells, and subsequently identified much
lower b-catenin mRNA expression in SCs from patients
with MM compared with those in primary myeloma cells
and normal SCs, indicating the inhibition of Wnt signal-
ing in patients’ SCs in contrast to its activation in
myeloma cells. Then we demonstrated that the mRNA
expression levels and the DKK-1 protein binding capabil-
ity of DKK-1binding receptors LRP5/6 and Krm1/2 in
SCs from patients with MM were significantly higher
than those in SCs from healthy donors and those in MM
cells, and also found coculture with rhDKK-1 or MM
cells in the presence or absence of a Transwell insert
could up-regulate the mRNA expression of LRP5/6 and
Krm1/2, and down-regulate b-catenin mRNA expression
in normal human SCs. Thus, we concluded that, com-
pared with myeloma cells in the same BM milieu, the
SCs overexpressed DKK-1 binding receptor in response
to DKK-1, which results in their intracellular Wnt signal-
ing inhibition.
Materials and methods
Reagents and Cytokines
Recombinant human DKK-1(rhDKK-1) was purchased
from R&D Systems (Minneapolis, MN, US). pcDNA3.1
(-)-DKK-1 vector was a generous gift from Dr Junzhou
Niu, the fourth Military Medical University(Xian,
China). Unless stated otherwise, all other chemical and
tissue culture reagents were purchased from Sigma
Aldrich Chemical Company (St. Louis, MO, US).
Patients
We studied 12 hospitalized patients with newly diag-
nosed MM [13] between October 2007 and January
2009 in our department. The clinical features are shown
in Table 1. In addition, 10 healthy donors (6 males and
4 females) with the median age of 60 years, ranging
from 40 to 72, were included in the study. Each healthy
donor was examined to ensure that there was no evi-
dence of bone disease (osteoporosis or osteoarthritis).
Bone marrow aspirates were obtained from the iliac
crest of all patients with MM and healthy donors at
Table 1 Clinical features of MM patients
No. patients 12
Gender 7M-5F
Age median (Range) 61(35-76)
Type of M-protein IgG(5), IgA(3), IgD(1).
Light chain(2), non-secretory(1)
Stage at diagnosis (Durie-
Salmon)
Stage IIA: 3(25%)
Stage IIIA:7 (58.3%)IIIB: 2(16.7%)
Bone disease status at diagnosis no osteolytic lesions:2(16.7%)
one to three lytic bone lesions:4
(33.3%)
more than three lytic lesions:6(50%)
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the Declaration of Helsinki and our local ethics commit-
tee. The approval of the study was obtained from the
Second Military Medical University for Medical Science
Institutional Review Board.
Cells and Cell Culture Conditions
Cell lines
Human myeloma cell lines (HMCLs) RPMI-8226, NCI-
H929, U266, LP-1, CZ-1, KM-3, Sko-007 were used in
this study. NCI-H929 was introduced from Dr. Margaret
H.L. Ng (Prince of Wales Hospital, Chinese University
of Hong Kong). RPMI-8226 (CCL-155™), Sko-007(CRL-
8033-1™) and U266 (TIB-196™) were obtained from
American Type Culture Collection (ATCC). LP-1 secret-
ing IgG l light chain was kindly provided by Dr. Hallek
(Laboratorium für Molekulare Biologie, Genzentrum,
Ludwig-Maximilians-Universität München, Germany).
CZ-1 secreting l light chain was established from the
bone marrow of an advanced stage patient with MM
classified as l light chain type in our laboratory [14].
KM-3, a non-secreting MM cell line, was conserved in
our own laboratory. All the cell lines used in this study
were stored in liquid nitrogen in our laboratory. Before
experiments, cells were immediately cultured after thaw-
ing in RPMI 1640 medium (Sigma-Aldrich, St. Louis,
MO, USA) containing 10% fetal bovine serum, 200
units/ml penicillin, 200 g/ml streptomycin, minimal
essential vitamins, sodium pyruvate, and glutamine.
Primary human multiple myeloma cells and SCs
Primary multiple myeloma cells were isolated from BM
mononuclear cells (BMMNC) of multiple myeloma
patients at diagnosis by immunomagnetic beads using
anti-CD138 monoclonal antibody (mAb)-coated
microbeads (MACS, Miltenyi Biotec). Only samples with
purity >90%, checked by flow cytometry, were used
immediately after purification in the study.
Human BM SCs (HMSC) were obtained from primary
BM adherent cells after an attachment period and cultured
in Dulbecc’s Modified Eagle Medium(DMEM), containing
15% heated-inactivated FBS, penicillin (100 U/ml), strepto-
mycin (100 mg/ml), and 4 mM L-glutamine.
Cell cocultures
A series of coculture experiments were done with
HMCL RPMI-8226 or NCI-H929 (1 × 10
6cells) and con-
fluent HMSC of healthy donors (5 × 10
5cells). Myeloma
cells were added directly to the cultures or placed in a
Transwell insert (Corning Biotec) in RPMI 1640 with
10% FCS for 24 to 72 h. At the end of culture period,
cocultures were depleted of myeloma cells using a nega-
tive immunoselection with anti-CD138 mAb (MACS,
Miltenyi Biotec, Bergisch Gladbach, Germany).
In selected experiments, HMSC of healthy donors (5 ×
10
5cells) were incubated in the presence of rhDKK-1
(100-700 ng/mL) for 48 to 72 h.
Real-time PCR
Total RNA was isolated using TRIzol reagent (Invitro-
gen, Calsbad, CA). Quantitative PCR (qPCR) was per-
formed using an ABI Prism 7500 sequence detection
system (Applied Biosystems, F o s t e rC i t y ,C A ) .P r i m e r s ,
including LRP5/6, Krm1/2 and b-catenin were designed
using the ABI Primer Express 2 software. Primer
sequences are: LRP5, 5- GGGCCACTCTGGCTTCTCT
-3(forward) and 5- CATCACAGTTCACATTTCT-
CATGTTT -3(reverse); LRP6, 5-GTGAGAGAAGAGAA
CGCGAGAAG-3(forward) and 5- GTCCCGTCTGT
TTGCATAAAGC -3(reverse); Krm1, 5- CAGCCCC-
GATGCATCCT -3(forward) and 5- TCCGCGTATAA
GTGCTTGTGA-3(reverse); Krm2, 5- TGGCGCT
ACTGCGACATC -3(forward) and 5-GTCCACAAAG-
CATCCCAGGTA -3(reverse); b-catenin, 5- TGCCAT
TCCACGACTAGTTCAG -3(forward) and 5- CGTACG
GCGCTGGGTATC-3(reverse). Using Reaction Ready
First-Strand cDNA Synthesis kit (Toyobo Biotec), 1 μg
total RNA was reverse transcribed and then real-time
PCR was done by adding cDNA directly to PCR Master
Mix containing SYBR Green and References Dyes
(Toyobo Biotec). The mixtures were then aliquoted into
96-well PCR array plates, which profile the expression
of LRP5/6, Krm1/2 and b-catenin plus controls. Each
c D N As a m p l ew a sa n a l y z e di nt r i p l i c a t ei np a r a l l e lw i t h
GAPDH as a control. Thermal cycling was done accord-
ing to the manufacturer’s protocol (Ta, 60°C; total
cycles, 40-45). Finally, we determined the fold changes
in expression byΔΔCt as described previously [15].
Western Blot Analysis
Total cell lysates for Western blots were obtained using a
commercial kit (Sigma Chemical). Lysates were separated
by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE), transferred to polyvinylidene
difluoride membranes, and then blocked in TBS plus 5%
BSA and 0.1% TWEEN for 1 hour, before incubating
with anti-DKK-1 (Milipore, Bedford, MA). Anti-b-actin
(Sigma-Aldrich, St.Louis, MO, USA) was used as control.
Transfectants, expressions and purification
To generate a DKK-1 expressing cell line, 293T cells
were transiently transfected, using LipofectA-
MINE™2000 reagent (Invitrogen, Carlsbad, CA), with a
pcDNA3.1(-)-DKK-1 vector carrying a DKK-1 cDNA,
according to manufacturer’s instructions. In the super-
natant, His-DKK-1 fusion protein was collected. With
the Ni-Agarose His protein purification kit, DKK-1
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(Milipore, Bedford, MA) and anti-His antibody (Sigma
A l d r i c h ,S t .L o u i s ,U S ) ,H i s - D K K - 1f u s i o np r o t e i ni n
the supernatant was identified by Western blotting
analysis.
Flow cytometry
Flow cytometry (FCM) was adopted to determine the
expression level of DKK-1-binding receptors on the
myeloma cells and SCs. Primary myeloma cells and SCs
from MM patients and healthy donors (2 × 10
5cells)
were treated with different concentrations of recombi-
nant His-DKK-1 fusion protein for 30 minutes on ice,
washed 2 times and resuspended in phosphate-buffered
saline (PBS). Then, fluorescein isothiocyanate (FITC)-
labeled anti-6×His polyclonal antibodies (Abcam) were
added to cell suspensions, incubated for 30 minutes on
ice, and washed 3 times before analysis. Samples were
analyzed using a flow cytometer (Beckman Coulter,
Fullerton, CA). Cell suspensions without FITC-labeled
anti-6×His polyclonal antibodies were used as negative
controls. Mean fluorescence intensity (MFI) is used as
index of detection.
Statistical analysis
Statistical significance was analyzed by one-way
ANOVA using SPSS version 13.0 software and consid-
ered significant given P less than or equal to 0.05. Data
were presented as means ± SEM unless otherwise stated.
Results
Expression of DKK-1 protein by human MM cells
We examined the expression of DKK-1 protein in 6
HMCLs, and 5 freshly purified primary CD138+ mye-
loma cells and 4 SCs from patients with MM by western
blotting. It showed that DKK-1 protein was obviously
expressed in RPMI-8226, NCI-H929 and LP-1, and
weakly expressed in U266, CZ-1 and KM-3. DKK-1
protein expression was positive in 3 of the 5 primary
CD138+ myeloma cells and negative in all the SCs from
4 patients with MM (Fig. 1).
mRNA expression of LRP5/6, Krm1/2 and b-catenin in
HMCLs, CD138+ primary myeloma cells and SCs from
patients with MM and healthy donors
LRP5/6 and Krm1/2 mRNA expression levels in SCs
from patients with MM (C) were significantly higher than
those in SCs from healthy donors (D) (p < 0.001) and
those in CD138+ primary myeloma cells (B) (p < 0.01).
b-catenin mRNA expression levels in HMCLs and
CD138+ primary myeloma cells were obviously higher
than those in SCs from patients with MM and healthy
donors (p < 0.05). There were no significant differences
in the b-catenin mRNA expression levels between the
S C sf r o mh e a l t h yd o n o r sa n dt h o s ef r o mp a t i e n t sw i t h
MM (p > 0.05) (Fig. 2).
Influences of MM cells on the mRNA expression of
LRP5/6, Krm1/2 and b-catenin in SCs from healthy
donors in coculture
The mRNA expressions of LRP5/6, Krm1/2 and b-catenin
were detected in SCs from healthy donors after 24-72 h of
coculture with RPMI-8226 or NCI-H929 in the presence
or absence of a Transwell insert. We found a significant
up-regulation of LRP5 (fold change, 3.5/7), LRP6 (fold
change, 4/5), Krm1 (fold change, 4/7) and Krm2 (fold
change, 5/4.5) together with the corresponding down-
regulation of b-catenin (fold change, -1.3/-2.7) in SCs
from healthy donors after 48h/72 h coculture with RPMI-
8226 in the presence or absence of a Transwell insert. No
significant influence on the gene expression was observed
at 24 h after coculture (Fig. 3). Similar results were
obtained with NCI-H929 in coculture (data not shown).
Effects of rhDKK-1 on the mRNA expression of LRP5/6,
Krm1/2 and b-catenin in SCs from healthy donors in
coculture
The mRNA expressions of LRP5/6, Krm1/2 and b-catenin
were examined in SCs from healthy donors after 48-72 h
of coculture with rhDKK-1 at the concentrations ranging
from 100 to 700 ng/ml. The mRNA expression levels of
LRP5/6 and Krm1/2 in SCs from healthy donors were
time-dependently and dose-dependently elevated after the
coculture with rhDKK-1. Correspondingly, the mRNA
expressions of b-catenin in SCs significantly decreased in a
dose-dependent manner (Fig. 4).
The quantitative analysis of DKK-1 binding receptors on
the myeloma cells and SCs
Flow cytometry results showed that recombinant
His-DKK-1 fusion protein could specifically bind the
DKK-1 binding receptors on the myeloma cells and SCs.
The mean fluorescence intensity (MFI) of the DKK-1
related receptors on myeloma cells (B), SCs from
healthy donors (A) and patients with MM (C) were
(58.6 ± 17.2), (20.8 ± 8.4) and (104.5 ± 32.1), respec-
tively (Fig. 5). There were significant differences among
the three groups (P < 0.05).
Discussion
MM is a debilitating and incurable malignancy of anti-
body-secreting plasma cells that predominantly accumu-
late in the BM. The tropism of myeloma cells for BM
suggests that BM provides a unique microenvironment
favoring the growth and survival of MM cells. The inter-
action between myeloma cells and osteoclasts that con-
tributes to the tumor growth and the aggravation of
osteolytic lesions has been well recognized. The recent
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Page 4 of 9Figure 1 Expression of DKK1 protein by human multiple myeloma cells. DKK1 protein expression was evaluated by Western blot analysis in
cell lysates from HMCLs, purified CD138+ multiple myeloma cells and SCs of multiple myeloma patients. DKK-1 protein expression was obviously
expressed in RPMI-8226, NCI-H929 and LP-1 and weakly expressed in U266, CZ-1 and KM-3. DKK-1 protein expression was positive in 3 of the 5
primary CD138+ myeloma cells and negative in all the SCs from 4 patients with MM. (HMCLs: RPMI-8226, U266, NCI-H929, LP-1, CZ-1, KM-3.
MM1-5: freshly purified CD138+ myeloma cells of 5 MM patients. HMSC1-4: Human BM SCs from 4 MM patients)
Figure 2 LRP5/6, Krm1/2 and b-catenin gene expression of HMCLs, CD138+ primary myeloma cells and SCs from patients with MM and
healthy donors. HMCLs include RPMI-8226, NCI-H929, LP-1, U266, CZ-1, KM-3 and Sko-007. B: CD138+ primary myeloma cells. C: SCs from patients
with MM. D: SCs from healthy donors. LRP5/6 and Krm1/2 mRNA expression in SCs from patients with MM (C) were significantly higher than those
in SCs from healthy donors (D) (p < 0.001) and those in CD138+ primary myeloma cells (B) (p < 0.01). b-catenin mRNA expression in HMCLs and
CD138+ primary myeloma cells was obviously higher than those in SCs from patients with MM and healthy donors (p < 0.05). There was no
significant differences in the b-catenin mRNA expression levels between SCs from healthy donors and those from patients with MM (p > 0.05).
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loma indicates the importance of osteoblasts in the lytic
process [8].
Canonical Wnt signaling is extremely required in
osteoblastogenesis and normal bone metabolism, and
secretion of Wnt signaling antagonists by MM cells is
thought to contribute to the bone-destructive process as
well as disease progression by inhibiting the differentia-
tion and maturation of osteoblasts. The positive correla-
tion between the DKK-1 expression and the osteolytic
lesions has been identified [16]. It has been shown that
primary myeloma cells from osteolytic MM patients
significantly overexpressed the Wnt inhibitor DKK-1 in
comparison with the plasma cells from patients with
monoclonal gammopathy of undetermined significance
(MGUS) and normal plasma cells. In the present study,
we demonstrated that most of the HMCLs and the pri-
mary myeloma cells produced DKK-1 protein, consistent
with the previous reports [17].
It is definite that Wnt signaling is activated in myeloma
cells, and the key signaling molecule b-catenin accumu-
lates in the nuclei and activates the transcription of its tar-
get genes [18]. On the contrary, blockade of Wnt signaling
in MSCs by DKK-1 has been shown to result in suppres-
sion of osteoblastic bone formation which contributes to
the systemic bone loss and osteolytic bone lesions in
Figure 3 Effects of MM cells on the mRNA expressions of LRP5/6, Krm1/2 and b-catenin in SCs from healthy donors in coculture with
RPMI-8226. A1: SCs from healthy donors. A2: SCs from healthy donors in coculture with RPMI-8226 in the absence of a Transwell insert. A3: SCs
from healthy donors in coculture with RPMI-8226 in the presence of a Transwell insert. LRP5/6, Krm1/2 and b-catenin gene expressions were
detected in SCs from healthy donors after 24h-72 h coculture with RPMI-8226 in the presence or absence of a Transwell insert. No significant
effect on the gene expression was observed after 24 h coculture. After 48 h, a significant up-regulation of LRP5(fold change, 3.5), LRP6 (fold
change, 4), Krm1(fold change, 4) and Krm2 (fold change,5) together with an down-regulation of b-catenin (fold change, -1.3) in SCs from healthy
donors were seen whether in the presence or absence of a Transwell insert. After 72 h, mRNA expression of LRP5(fold change, 7), LRP6 (fold
change, 5), Krm1(fold change, 7) and Krm2 (fold change, 4.5) were elevated, meanwhile mRNA expression of b-catenin (fold change, -2.7) was
decreased.
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sion levels in myeloma cells were considerably higher than
those in SCs, and that b-catenin expression levels in SCs
from patients with MM were even a little lower than those
from healthy donors, suggesting that Wnt signaling is
highly inhibited in SCs from patients with MM. Given the
fact of osteoclast activation and the consequent enhanced
bone resorption in MM, the inhibition of Wnt signaling in
SCs is considered to contribute to attenuated bone forma-
tion and aggravated imbalance of bone metabolism.
Though in the same tumor-stroma milieu, DKK-1
produced by MM cells could inhibit the Wnt signaling
in osteoblast progenitors, but failed to block the Wnt
signal transduction in MM cells. The discrepency in the
condition of canonical Wnt signaling between SCs and
myeloma cells in response to DKK-1 drove us to investi-
gate the expression of DKK-1 binding receptor on the
cell surface.
Krm was originally discovered as a novel transmem-
brane protein containing the kringle domain. Krm1/2 is
high-affinity receptors for DKK. DKK-1 and the Wnt
coreceptor, LRP5/6, interact with Krm1/2 to form a
ternary complex and inhibit Wnt/beta-catenin signaling
[20]. In the present study, we found the gene expression
levels of LRP5/6 and Krm1/2 in SCs from patients with
MM were much higher than those of primary myeloma
cells, and those of normal SCs. The differential expres-
sion of DKK-1 binding receptors on the surface of SCs
and myeloma cells probably lead to their diverse Wnt
signal transduction. More importantly, the results are
Figure 4 Effects of rhDKK1 on the mRNA expression of LRP5/6, Kremen1/2 and b-catenin in SCs from healthy donors in coculture. The
mRNA expression of LRP5/6 and Krm1/2 were significantly elevated and the mRNA expression of b-catenin was decreased in SCs from healthy
donors after 48h-72 h of coculture with rhDKK1 at concentration of 700 ng/ml.
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protein binding capability of these DKK-1 binding
receptors. We used recombinant His-DKK-1 fusion pro-
tein and FITC-labeled anti-His polyclonal antibodies to
determine the expression and binding capacity of DKK-
1 receptor protein on the surface of myeloma cells and
SCs. It was demonstrated that the amount of DKK-1
binding receptor protein on the SCs from patients with
MM were much higher than those on the primary mye-
loma cells and on the SCs from healthy donors. Mao et
al. [11] found that DKK-1 binds readily to cells overex-
pressing LRP5/6, but not cells overexpressing Wnt or
Frizzled. Compared with the myeloma cells in the same
BM microenvironment, SCs from patients with MM
overexpressed LRP5/6 and Krm1/2, and thus had higher
affinity to DKK-1, contributing to the different response
to DKK-1.
In our study, SCs from healthy donors were cocul-
tured with HMCLs, RPMI-8226 and NCI-H929. We
found significant upregulation of LRP5/6 and Krm1/2
mRNA expression and down-regulation of b-catenin
mRNA expression in SCs in similar degrees in the pre-
sence or absence of a Transwell insert after 48-72 h
coculture. Furthermore, similar results in the regulation
of LRP5/6, Krm1/2 and b-catenin were also found in
SCs from healthy donors after the treatment of rhDKK-
1 at a high dose. It has also been identified in our study
that both RPMI-8226 and NCI-H929 secrete DKK-1
protein. All of these results mightily suggest that mye-
loma cells could promote expressions of LRP5/6 and
Krm1/2 on SCs in coculture via DKK-1 secretion. Like-
wise, the highly expressed DKK-1 binding receptors on
the SCs from MM patients in our study probably result
from the DKK-1 secretion by myeloma cells in the same
BM milieu. Noteworthy, rhDKK-1 can induce the
foresaid alterations of gene expressions only at a high
concentration (700 ng/ml) in our study, in accordance
with the earlier reports that DKK-1 inhibited the differ-
entiation of SCs/osteoprogenitor cells to osteoblast only
at high concentrations [21].
Taken together, our study elucidated the mechanism
by which myeloma cells and SCs in the same BM micro-
environment respond differently to DKK-1 produced by
MM cells. In comparison with myeloma cells, SCs from
MM patients overexpress DKK-1 binding receptors
LRP5/6 and Krm1/2, which probably lead to the block-
ade of intracellular Wnt signaling in SCs. Our study
provides a novel insight into mechanisms of myeloma
associated osteolytic lesions.
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